Our next ADITL takes us to Intermountain Healthcare in Utah following Mary Hutton, PharmD! Be sure to keep up throughout the month as we approach #IDPharmacistsDay 💊🦠
Oral Beta-Lactams, Fluoroquinolones, or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Uncomplicated Escherichia coli or Klebsiella species Bacteremia from a Urinary Source
✅ Just Accepted
🔓 Open Access
https://t.co/F2r9b4iwAG
via @jvilletti
🆕️🔥Multicenter observational cohort
Oral Beta-Lactams Fluoroquinolones, or Trim Sulfa for Definitive Rx of Uncomplicated E.coli or Klebsiella species Bacteremia from a Urinary Source
High-bioavailability βLs asociated w higher recurrence rates
BL Dose⛔️ https://t.co/V99hB0U6TC
New from @whithartlage11 et al at @UWTASP:
Authors found that inappropriate treatment of asymptomatic bacteriuria is common in critical-access hospitals and highlight areas to focus stewardship initiatives in these settings
📄: https://t.co/CrrbDuLC6l
From @jvilletti, @stephshealymay et al from @IntermtnMedCtr: Another opportunity for ASP in the ED! Patients with BPCUS had ⬆️ readmissions despite abx. Key: Emphasize close f/u for an unknown diagnosis over abx treatment of a + urine! #stewardship https://t.co/MvhlwwZXbi
Very excited to share our tele-COVID intervention and the impact on early antibiotic use in @JHospMedicine. ITS demonstrated >5,000 antibiotic days avoided. Transfers were also significantly reduced.
https://t.co/iaVGQHO6UD